Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51.

Lei Huang, Ye Yang, Dongxia Duan, Li Dai, Bingxin Zhai, Bingjun Qian

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.Journal of clinical medicine · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lei HuangDepartment of Pharmacology and Medicinal Chemistry, Jiangsu Medical College, Yancheng 224005, China.

Ye YangDepartment of Pharmacology and Medicinal Chemistry, Jiangsu Medical College, Yancheng 224005, China.

Dongxia DuanDepartment of Preventive Medicine, Jiangsu Medical College, Yancheng 224005, China.

Li DaiDepartment of Preventive Medicine, Jiangsu Medical College, Yancheng 224005, China.

Bingxin ZhaiDepartment of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.

Bingjun QianDepartment of Pharmacology and Medicinal Chemistry, Jiangsu Medical College, Yancheng 224005, China.

Funding

the Jiangsu Medical College Innovative Research Team for Science and Technology 20254305the Natural Science Foundation of the Jiangsu Higher Education Institutions of China 21KJB360013the Science and Technology Project of Yancheng YCBK2024008

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) cells with intact homologous recombination (HR) repair mechanism can survive treatment with Olaparib, which further limits the clinical application of PARP1/2 inhibitors. Previous studies have demonstrated that inhibition of indoleamine 2,3-dioxygenase (IDO) can enhance the sensitivity of human tumor cells to PARP1/2 inhibitors. However, the mechanisms underlying their synergistic effects in the treatment of TNBC remain unclear. Herein, we demonstrate that the combination of Olaparib and Epacadostat significantly reduces the proliferation of BRCA-proficient MDA-MB-231 and MDA-MB-468 cells compared to either monotherapy. Mechanistically, Epacadostat reduces intracellular kynurenine and NAD

Indexed as

BRCA1 ProteinPhthalazinesPiperazinesRad51 RecombinaseSulfonamidesTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationDNA DamageDrug SynergismFemaleGene Expression Regulation, NeoplasticHumansMDA-MB-231 CellsBRCA1 ProteinBRCA1 protein, humanepacadostatolaparibOximesPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1RAD51 protein, humanRad51 RecombinaseReactive Oxygen SpeciesSulfonamidesBRCA-proficientHRIDO1NAD+PARP1/2ROSTNBC

Identifiers

PMID41900138

DOI10.3390/molecules31061039

PMCPMC13029597

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.